<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741165</url>
  </required_header>
  <id_info>
    <org_study_id>HX008-II-HCC-01</org_study_id>
    <nct_id>NCT04741165</nct_id>
  </id_info>
  <brief_title>Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Hanzhong biomedical co. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou Hanzhong biomedical co. LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1&#xD;
      antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with&#xD;
      unresectable hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 15 months</time_frame>
    <description>ORR was defined as the percentage of participants who have a complete response (CR) or a partial response (PR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>DOR was defined as the time from the first documented evidence of a response of CR or PR, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>OS was defined as the time from the date of beginning of HX008 administration until date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (TTP)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>TTP is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental: HX008+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: HX008+Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight &lt;60 kg) orally once a day (QD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX008</intervention_name>
    <description>200 mg administered as IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Experimental: HX008+Bevacizumab</arm_group_label>
    <arm_group_label>Experimental: HX008+Lenvatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Experimental: HX008+Bevacizumab</arm_group_label>
    <other_name>AVASTIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Administered orally once a day during each 21-day cycle</description>
    <arm_group_label>Experimental: HX008+Lenvatinib</arm_group_label>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understood and signed an informed consent form.&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 75 years old, male or female.&#xD;
&#xD;
          -  Has histologically- or cytologically-confirmed diagnosis of unresectable&#xD;
             hepatocellular carcinoma.&#xD;
&#xD;
          -  Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not&#xD;
             amenable to locoregional therapy or refractory to locoregional therapy, and not&#xD;
             amenable to a curative treatment approach.&#xD;
&#xD;
          -  Child-Pugh class A and B (≤7 points).&#xD;
&#xD;
          -  Has not received any systematic treatment for HCC.&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Score.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  Has at least one measurable disease based on RECIST 1.1.&#xD;
&#xD;
          -  Has adequate organ function as defined in the protocol.&#xD;
&#xD;
          -  Female participants of childbearing potential should have a negative pregnancy within&#xD;
             7 days before the randomization. Male and female participants should agree to use an&#xD;
             adequate method of contraception during the experiment and 1 year after the last&#xD;
             administration of the test drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented fibrolamellar hepatocellular carcinoma,&#xD;
             sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.&#xD;
&#xD;
          -  Diagnosed additional malignancy within 3 years prior to the first dose of trial, with&#xD;
             the exception of curatively treated basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin,curatively resected in situ cervical or non-muscle invasive&#xD;
             bladder cancers.&#xD;
&#xD;
          -  Has received locoregional therapy or surgery within 4 weeks prior to the first dose of&#xD;
             trial treatment; received palliative radiotherapy or herbal medicine within 2 weeks&#xD;
             prior to the first dose of trial treatment;&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          -  HBV-DNA&gt;2000 IU/mL or 10^4 copy/mL; HCV-RNA&gt;10^3 copy/mL.&#xD;
&#xD;
          -  Has had esophageal or gastric variceal bleeding within the last 6 months.&#xD;
&#xD;
          -  Portal vein tumor thrombus (PVTT) involves both the main trunk and contralateral&#xD;
             branch or upper mesenteric vein. Inferior vena cava tumor thrombus.&#xD;
&#xD;
          -  Other obvious hemorrhagic tendency or evidence on important coagulation disorder.&#xD;
&#xD;
          -  Serious cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
          -  Inability to swallow tablets, malabsorption syndrome or any other condition that&#xD;
             affects gastrointestinal absorption.&#xD;
&#xD;
          -  Serious, uncured wound, active ulcer or untreated bone fracture.&#xD;
&#xD;
          -  Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious&#xD;
             moderate peritoneal effusion at screening.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          -  Has received a major surgery within 4 weeks prior to the first dose of tiral&#xD;
             treatment.&#xD;
&#xD;
          -  Has received system treatment with corticosteroids (dose &gt;10mg/day prednison or other&#xD;
             therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has a history of non-infectious pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has known active tuberculosis (Bacillus tuberculosis)&#xD;
&#xD;
          -  Has a history of testing positive for human immunodeficiency virus (HIV), or known&#xD;
             acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Co-infection of HBV and HCV.&#xD;
&#xD;
          -  Any serious acute and chronic infection within 4 weeks prior to the first dose of&#xD;
             trial treatment, or infection requiring systemic antibacterial, antifungal or&#xD;
             antiviral therapy within 2 weeks prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has participated in other anticancer drug clinical trials within 4 weeks.&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  According to the judgement of the investigators, there are other factors that may lead&#xD;
             to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianqiang Cai</last_name>
    <phone>010-67781331</phone>
    <email>caijianqiang188@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fist Affiliated Hospital of USTC(Anhui Provincial hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lianxin Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqiang Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianhai Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences, shenzhen center</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518116</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Che Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jufeng Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohai Mao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated University of Nanhua University</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenxiang Dai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Lv</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bo Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianqiang Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Lishui City</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfei Tu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

